LGP5 NPV
Risk adjusted net present value: What is the current valuation of Merck’s MK-0616?
MK-0616 is a peptide commercialized by Merck, with a leading Phase III program in Heterozygous familial hypercholesterolemia (heFH). According to…
Risk adjusted net present value: What is the current valuation of AstraZeneca’s Puxitatug Samrotecan?
Puxitatug Samrotecan is a monoclonal antibody conjugated commercialized by AstraZeneca, with a leading Phase II program in Metastatic Bile Duct…
Risk adjusted net present value: What is the current valuation of Celltrion’s Tocilizumab biosimilar?
Tocilizumab biosimilar is a monoclonal antibody commercialized by Celltrion, with a leading Phase III program in Rheumatoid Arthritis. According to…
Risk adjusted net present value: What is the current valuation of Legend Biotech’s LB-1908?
LB-1908 is a gene-modified cell therapy commercialized by Legend Biotech, with a leading Phase I program in Adenocarcinoma Of The…
Risk adjusted net present value: What is the current valuation of Gracell Biotechnologies’s GC-012F?
GC-012F is a gene-modified cell therapy commercialized by Gracell Biotechnologies, with a leading Phase II program in Relapsed Multiple Myeloma.…
Risk adjusted net present value: What is the current valuation of SanBio’s Vandefitemcel?
Vandefitemcel is a gene-modified cell therapy commercialized by SanBio, with a leading Phase II program in Traumatic Brain Injury. According…
Risk adjusted net present value: What is the current valuation of Amgen’s Ustekinumab Biosimilar?
Ustekinumab Biosimilar is a monoclonal antibody commercialized by Amgen, with a leading Phase III program in Plaque Psoriasis (Psoriasis Vulgaris).…
Risk adjusted net present value: What is the current valuation of Oculis’s Dexamethasone Acetate?
Dexamethasone Acetate is a small molecule commercialized by Oculis, with a leading Phase III program in Ocular Inflammation;Ocular Pain (Eye…
Risk adjusted net present value: What is the current valuation of Pyxis Oncology’s PYX-201?
PYX-201 is a monoclonal antibody conjugated commercialized by Pyxis Oncology, with a leading Phase I program in Thyroid Cancer. According…
Risk adjusted net present value: What is the current valuation of Cingulate’s Dexmethylphenidate Hydrochloride?
Dexmethylphenidate Hydrochloride is a small molecule commercialized by Cingulate, with a leading Phase III program in Attention Deficit Hyperactivity Disorder…